Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease

  • Lijun Wang
  • for the Alzheimer’s Disease Neuroimaging Initiative
Original Article

Abstract

Cerebrospinal fluid (CSF) Neurogranin has recently been proposed as a potential biomarker for cognitive decline and brain injury in Alzheimer’s disease (AD). To test whether CSF Neurogranin levels are increased in AD and its association with cognitive decline, we examined 99 cognitively normal (CN) subjects, 171 patients with mild cognitive impairment (MCI), and 81 patients with AD in the cross-sectional study from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). The results showed that CSF Neurogranin was increased in both AD and MCI compared with controls. CSF Neurogranin was particularly high in patients with MCI and AD dementia with Aβ pathologic features. Neurogranin levels were significantly higher in females compared to males with MCI. Levels of Neurogranin between the males and females with AD and CN did not differ. Neurogranin levels were significantly higher in APOE ε4 carriers compared to APOE ε4 non-carriers with MCI. Levels of Neurogranin between the APOE ε4 carriers and APOE ε4 non-carriers with AD and CN did not differ. Elevated CSF Neurogranin levels were positively correlated with levels of total tau and P-tau in AD. The results indicated that CSF Neurogranin was increased at the prodromal stage of AD and might reflect synaptic injury as cognitive decline in AD.

Keywords

Alzheimer’s disease Neurogranin Cerebrospinal fluid Mild cognitive impairment 

Notes

Acknowledgements

Data collection and sharing for this project was funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study involving human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed Consent

Written informed consent was obtained from all participants or authorized representative.

References

  1. 1.
    Bertoni-Freddari C, Fattoretti P, Casoli T et al (1996) Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer’s type. Anal Quant Cytol Histol 18:209–213PubMedGoogle Scholar
  2. 2.
    Blennow K, Bogdanovic N, Alafuzoff I et al (1996) Synaptic pathology in Alzheimer’s disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele. J Neural Transm 103:603–618CrossRefPubMedGoogle Scholar
  3. 3.
    DeKosky ST, Scheff SW (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann Neurol 27:457–464CrossRefPubMedGoogle Scholar
  4. 4.
    Masliah E, Mallory M, Alford M et al (2001) Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology 56:127–129CrossRefPubMedGoogle Scholar
  5. 5.
    Scheff SW, Price DA, Schmitt FA et al (2007) Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology 68:1501–1508CrossRefPubMedGoogle Scholar
  6. 6.
    Diez-Guerra FJ (2010) Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity. IUBMB Life 62:597–606CrossRefPubMedGoogle Scholar
  7. 7.
    Portelius E, Zetterberg H, Skillback T et al (2015) Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer’s disease. Brain 138:3373–3385CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Janelidze S, Hertze J, Zetterberg H et al (2016) Cerebrospinal fluid Neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Ann Clin Transl Neurol 3:12–20CrossRefPubMedGoogle Scholar
  9. 9.
    Wellington H, Paterson RW, Portelius E et al (2016) Increased CSF Neurogranin concentration is specific to Alzheimer disease. Neurology 86:829–835CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Tarawneh R, D’Angelo G, Crimmins D et al (2016) Diagnostic and prognostic utility of the synaptic marker Neurogranin in Alzheimer disease. JAMA Neurol 73:561–571CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Kvartsberg H, Duits FH, Ingelsson M et al (2015) Cerebrospinal fluid levels of the synaptic protein Neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement 11:1180–1190CrossRefPubMedGoogle Scholar
  12. 12.
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurol 34 (7):939–944CrossRefGoogle Scholar
  13. 13.
    Folstein MF, Folstein SE, McHugh PR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  14. 14.
    Rosen WG, Mohs RC, Davis KL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry 141:1356–1364CrossRefPubMedGoogle Scholar
  15. 15.
    Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative subjects. Ann Neurol 65:403–413CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Olsson A, Vanderstichele H, Andreasen N et al (2005) Simultaneous measurement of beta-amyloid(1–42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 51:336–345CrossRefPubMedGoogle Scholar
  17. 17.
    Shaw LM, Vanderstichele H, Knapik-Czajka M et al (2011) Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI. Acta Neuropathol 121:597–609CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rosenmann H (2012) CSF biomarkers for amyloid and tau pathology in Alzheimer’s disease. J Mol Neurosci 47:1–14CrossRefPubMedGoogle Scholar
  19. 19.
    Zhong L, Gerges NZ (2010) Neurogranin and synaptic plasticity balance. Commun Integr Biol 3:340–342CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Zetterberg H, Blennow K (2015) Neurogranin levels in cerebrospinal fluid: a new addition to the Alzheimer disease diagnostic toolbox. JAMA Neurol 72:1237–1238CrossRefPubMedGoogle Scholar
  21. 21.
    Mons N, Enderlin V, Jaffard R et al (2001) Selective age-related changes in the PKC-sensitive, calmodulin-binding protein, neurogranin, in the mouse brain. J Neurochem 79:859–867CrossRefPubMedGoogle Scholar
  22. 22.
    Baudier J, Deloulme JC, Van Dorsselaer A et al (1991) Purification and characterization of a brain-specific protein kinase C substrate, Neurogranin (p17). Identification of a consensus amino acid sequence between Neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain. J Biol Chem 266:229–237PubMedGoogle Scholar
  23. 23.
    Xia Z, Storm DR (2005) The role of calmodulin as a signal integrator for synaptic plasticity. Nat Rev Neurosci 6:267–276CrossRefPubMedGoogle Scholar
  24. 24.
    Gerendasy DD, Sutcliffe JG (1997) RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes. Mol Neurobiol 15:131–163CrossRefPubMedGoogle Scholar
  25. 25.
    Represa A, Deloulme JC, Sensenbrenner M et al (1990) Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate. J Neurosci 10:3782–3792CrossRefPubMedGoogle Scholar
  26. 26.
    Dubois B, Hampel H, Feldman HH et al (2016) Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimers Dement 12:292–323CrossRefPubMedGoogle Scholar
  27. 27.
    Hellwig K, Kvartsberg H, Portelius E et al (2015) Neurogranin and YKL-40: independent markers of synaptic degeneration and neuroinflammation in Alzheimer’s disease. Alzheimers Res Ther 7:74CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Poirier J, Davignon J, Bouthillier D et al (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet 342:697–699CrossRefPubMedGoogle Scholar
  29. 29.
    Payami H, Montee KR, Kaye JA et al (1994) Alzheimer’s disease, apolipoprotein E4, and gender. Jama 271:1316–1317CrossRefPubMedGoogle Scholar
  30. 30.
    Farrer LA, Cupples LA, Haines JL et al (1997) Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer disease meta analysis consortium. Jama 278:1349–1356CrossRefPubMedGoogle Scholar
  31. 31.
    Liu CC, Liu CC, Kanekiyo T et al (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9:106–118CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    White F, Nicoll JA, Roses AD et al (2001) Impaired neuronal plasticity in transgenic mice expressing human apolipoprotein E4 compared to E3 in a model of entorhinal cortex lesion. Neurobiol Dis 8:611–625CrossRefPubMedGoogle Scholar
  33. 33.
    Wang C, Wilson WA, Moore SD et al (2005) Human apoE4-targeted replacement mice display synaptic deficits in the absence of neuropathology. Neurobiol Dis 18:390–398CrossRefPubMedGoogle Scholar
  34. 34.
    Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron 82:756–771CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Hyman BT (2011) Amyloid-dependent and amyloid-independent stages of Alzheimer disease. Arch Neurol 68:1062–1064CrossRefPubMedGoogle Scholar
  36. 36.
    Ingelsson M, Fukumoto H, Newell KL et al (2004) Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology 62:925–931CrossRefPubMedGoogle Scholar
  37. 37.
    Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 82:239–259CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institutes of Brain ScienceFudan UniversityShanghaiChina
  2. 2.Department of Neurology, Zhongshan Hospital, Shanghai Medical CollegeFudan UniversityShanghaiChina
  3. 3.State Key Laboratory of Medical NeurobiologyFudan UniversityShanghaiChina

Personalised recommendations